Elizabeth Garrett-Mayer to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Dose-Response Relationship, Drug.
Connection Strength
0.361
-
A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs. Clin Trials. 2015 Feb; 12(1):24-33.
Score: 0.091
-
Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. Am J Clin Nutr. 2012 Aug; 96(2):332-6.
Score: 0.078
-
The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006; 3(1):57-71.
Score: 0.050
-
Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. Clin Trials. 2012 Jun; 9(3):303-13.
Score: 0.019
-
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
Score: 0.019
-
Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading. Stat Med. 2011 Jul 30; 30(17):2070-80.
Score: 0.018
-
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol. 2009 Jun 10; 27(17):2816-22.
Score: 0.016
-
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14; 113(20):4841-52.
Score: 0.015
-
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 01; 26(25):4172-9.
Score: 0.015
-
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231.
Score: 0.014
-
Risks and benefits associated with novel phase 1 oncology trial designs. Cancer. 2007 Sep 01; 110(5):1115-24.
Score: 0.014
-
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2005 Dec 01; 11(23):8413-7.
Score: 0.012